Acquired Bleeding Disorder
Pipeline by Development Stage
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 25 trials with date data
Clinical Trials (25)
Total enrollment: 4,197 patients across 25 trials
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
Factor VIIa in Acute Intracerebral Haemorrhage
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Use of Activated Recombinant FVII in Spinal Surgery
Use of NovoSeven® in Active Variceal Bleeding
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage
Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury